Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c

Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

November 14, 2019 4:02 PM EST

- Conference call and webcast to be hosted today at 4:30pm EDT

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today reported financial results for the three and nine months ended September 30, 2019 and recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.

As we look forward to results from the AURORA Phase 3 trial for LN by the end of this year, the organization has been preparing for... More